Abstract:Hypoxia-inducible factors (HIFs) regulate the transcription of genes that mediate the response to hypoxia. HIFs are constantly expressed and degraded under normoxia, but stabilized under hypoxia. HIFs have been widely studied in physiological and pathological conditions and have been shown to contribute to the pathogenesis of various vascular diseases. In clinical settings, the HIF pathway has been studied for its role in inhibiting carcinogenesis. HIFs might also play a protective role in the pathology of ischemic diseases. Clinical trials of therapeutic angiogenesis after the administration of a single growth factor have yielded unsatisfactory or controversial results, possibly because the coordinated activity of different HIF-induced factors is necessary to induce mature vessel formation. Thus, manipulation of HIF activity to simultaneously induce a spectrum of angiogenic factors offers a superior strategy for therapeutic angiogenesis. Because HIF-2α plays an essential role in vascular remodeling, manipulation of HIF-2α is a promising approach to the treatment of ischemic diseases caused by arterial obstruction, where insufficient development of collateral vessels impedes effective therapy. Eukaryotic initiation factor 3 subunit e (eIF3e)/INT6 interacts specifically with HIF-2α and induces the proteasome inhibitor-sensitive degradation of HIF-2α, independent of hypoxia and von Hippel-Lindau protein. Treatment with eIF3e/INT6 siRNA stabilizes HIF-2α activity even under normoxic conditions and induces the expression of several angiogenic factors, at levels sufficient to produce functional arteries and veins in vivo. We have demonstrated that administration of eIF3e/INT6 siRNA to ischemic limbs or cold-injured brains reduces ischemic damage in animal models. This review summarizes the current understanding of the relationship between HIFs and vascular diseases. We also discuss novel oxygen-independent regulatory proteins that bind HIF-α and the implications of a new method for therapeutic angiogenesis using HIF stabilizers.

Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies

Regulation of angiogenesis by hypoxia and hypoxia-inducible factors

Hypoxia-Inducible Factor as an Angiogenic Master Switch

Targeting hypoxia signaling pathways in angiogenesis

Hypoxia-inducible factor-1 in tumour angiogenesis.

Hypoxia-inducible Factor-1 in Tumour Angiogenesis

Hypoxia Pathway Proteins and Their Impact on the Blood Vasculature

Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer

Hypoxia-Inducible Factor 1 in Lower Limb Ischemia

Novel Therapeutic Targets for Hypoxia-Related Cardiovascular Diseases: The Role of HIF-1

Hypoxia-inducible factors: roles in cardiovascular disease progression, prevention, and treatment

The Regulatory Mechanism of Hypoxia-inducible Factor 1 and its Clinical Significance

Hypoxia-Inducible Factor Regulates Endothelial Metabolism in Cardiovascular Disease

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

Hypoxia inducible factor as a therapeutic target for atherosclerosis

HIF-1: structure, biology and natural modulators

Hypoxia-inducible factor 1 in autoimmune diseases.

Hypoxia-inducible Factor-1α Pathway in Cerebral Ischemia: From Molecular Mechanisms to Therapeutic Targets

HIF-1α pathway: role, regulation and intervention for cancer therapy

Regulation of glycolysis by the hypoxia‐inducible factor (HIF): implications for cellular physiology

Targeting HIF-1 for cancer therapy